POINT Biopharma Global Inc. (PNT)
| Market Cap | 1.47B |
| Revenue (ttm) | 243.69M |
| Net Income (ttm) | 96.55M |
| Shares Out | 106.57M |
| EPS (ttm) | 1.10 |
| PE Ratio | 12.56 |
| Forward PE | 73.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,346,848 |
| Open | 13.83 |
| Previous Close | 13.72 |
| Day's Range | 13.64 - 13.93 |
| 52-Week Range | 6.39 - 14.00 |
| Beta | -0.05 |
| Analysts | Buy |
| Price Target | 13.00 (-5.18%) |
| Earnings Date | Nov 13, 2023 |
About PNT
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the tr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for PNT stock is "Buy." The 12-month stock price forecast is $13.0, which is a decrease of -5.18% from the latest price.
News
Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15
Eli Lilly , on Monday, gave Point Biopharma Global shareholders more time to sell their stock to the drugmaker amid low participation since the offer price was below the current stock price of the rad...
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
INDIANAPOLIS , Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("...
Eli Lilly extends tender offer to buy Point Biopharma after low participation
Eli Lilly on Friday extended the deadline for Point Biopharma Global shareholders by about two weeks to Dec. 1 to sell their stock, due to low participation.
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023
INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares (...
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma
INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect transfer of c...
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
Announced a definitive agreement to be acquired by Lilly for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion); transaction expected to close near the end of 20...
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("...
POINT BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of POINT Biopharma Global, Inc. - PNT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of POINT Biopharma ...
Eli Lilly Buys POINT Biopharma to Boost Its Cancer-Fighting Therapies
Shares of POINT Biopharma Global (PNT) skyrocketed over 80% in early trading on Tuesday after Eli Lilly (LLY) agreed to buy the radiopharmaceutical firm for $1.4 billion to expand its cancer-fighting ...
Shareholder Alert: Ademi LLP investigates whether POINT Biopharma Global, Inc. has obtained a Fair Price in its transaction with Eli Lilly
MILWAUKEE , Oct. 3, 2023 /PRNewswire/ -- Ademi LLP is investigating POINT (Nasdaq: PNT) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click her...
Point Biopharma stock nearly doubles on Eli Lilly deal
Shares of Point Biopharma Global Inc (NASDAQ: PNT) close to doubled this morning after Eli Lilly & Co (NYSE: LLY) announced plans of acquiring the cancer treatment company. Details of Lilly-Point agre...
PNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of POINT Biopharma Global, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of POINT Biopharma Global, Inc. (NASDAQ: PNT) to Eli Lilly for $12.50 per share in cash is f...
Eli Lilly to Buy Point Biopharma for $1.4 Billion
Eli Lilly will acquire radiopharmaceutical company Point Biopharma Global for $12.50 a share.
Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion
Eli Lilly and Co will buy cancer therapy developer Point Biopharma Global for $1.4 billion, the companies said on Tuesday.
Point Biopharma Global's stock jumps more than 80% after Lilly merger deal
Point Biopharma Global, Inc.'s PNT, +0.22% stock was up 83.4% in premarket trading on Tuesday after Eli Lilly & Co. LLY, +0.22% said it will pay $12.50 a share to acquire the Indianapolis-based cancer...
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
INDIANAPOLIS , Oct. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiop...
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first patie...
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (...
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
POINT's vertically integrated platform together with AdvanCell's lead-212 (²¹²Pb) generator technology enables both the development and scaled commercialization of ²¹²Pb-labeled radioligand therapies ...
POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI's Annual Congress
Auger electron and beta emitting isotope terbium-161 was paired with POINT's FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar to actinium-225 and lutetium-177 labeled PNT6555
POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023
Register online today at: https://hub.pointbiopharma.com/investor-day-june-2023
POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
PNT2004 program's phase 1 FRONTIER trial design to be presented Abstract to be released today at 5:00 PM ET, May 25 th Poster to be available starting at 9:00 AM ET, June 3 rd INDIANAPOLIS, May 25, 20...
POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer
POINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp. POINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp.
POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
U.S. FDA granted Fast Track designation for 177 Lu-PNT2002 for the treatment of mCRPC in April 2023
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiothe...